Previous studies also showed a significantly reduced expression of MLL2/KMT2D in breast cancer [11] and a decreased expression of MLL3/KMT2C in larynx carcinoma samples when compared to normal adjacent tissue from the same patients, with the lowest expression of MLL2/KMT2D and MLL3/KMT2C found in the most advanced tumors [10]. The gene discussed is KMT2D; the disease is breast cancer.